Hair growth agent (embodiments) and method for treating hair loss

Abstract

The invention relates to medicine and cosmetology. According to a first embodiment, a composition in the form of a gel for treating or preventing hair loss contains: 0.08-0.8% unfractionated heparin salt, 0.15-3% lipid nanocomplex emulsion, 0.5-2% thickener, 0.1-0.2% emulsifier, 0.03-1.3% neutralizing agent, 0.01-0.03% preservative, the remainder being water or a polyol. According to a second embodiment, a composition in the form of a gel for treating or preventing hair loss contains: 0.08-0.8% unfractionated heparin salt, 0.15-3% lipid nanocomplex emulsion, 0.005-0.02% peptide nanocomplex solution, 0.05-3% thickener, 0.1-0.2% emulsifier, 0.03-1.3% neutralizing agent, 0.01-0.03% preservative, the remainder being water.; According to a third embodiment, a composition in the form of a gel-cream for treating or preventing hair loss contains: 0.08-0.8% unfractionated heparin salts, 3-5% lipid nanocomplex emulsion, 0.05-3% thickener, 0.03-1.3% neutralizing agent, 0.01-0.03% preservative, 12-15% oils, 3-4% emulsifier, the remainder being water. According to a fourth embodiment a composition in the form of a gel-cream for treating or preventing hair loss contains: 0.08-0.8% unfractionated heparin salts, 3-5% lipid nanocomplex emulsion, 0.005-0.02% peptide nanocomplex solution, 0.05-3% thickener, 0.03-1.3% neutralizing agent, 0.01-0.03% preservative, 12-15% oils, 3-4% emulsifier, the remainder being water.; The method for treating or preventing hair loss caused by alopecia consists in the topical application to the area of hair loss of the above-mentioned compositions, selected according to the duration and extent of hair loss. The technical result is an increase in the range of means for treating hair loss (for example androgenic alopecia) without side effects.

Description

technical field [0001] The present invention relates to the field of aesthetic medicine and cosmetology, and in particular to the treatment of hair loss, compositions of unfractionated heparin sodium salt, lipoplexes and peptide nanocomplexes for topical application and the use of such compositions in areas of alopecia to induce and / or promote hair growth and / or methods of reducing hair loss. Background technique [0002] People know from the patent document "International application number is PCT / US2011 / 040470 (published by WIPO on December 22, 2011), international patent classification number is А61К8 / 73, and the applicant is Momenta Pharmaceutical Co., Ltd. (USA)" "Methods and compositions for promoting hair growth". [0003] The treatment method is to apply low-molecular-weight heparin (hereinafter referred to as LMWH) locally once a day on the required parts of the body for 3, 4, 12 weeks or longer, if the period is not determined. The patent author describes the com...

AI Technical Summary

Problems solved by technology

[0007] 1) There are no data on the use of gel cream in mice and humans, the authors only made some assumptions;

[0008] 2) There is a lack of results evaluating parenteral and topical low-molecular-weight heparins for the treatment of human alopecia, including androgenetic alopecia;

[0009] 3) It is not possible to switch to oral administration of the preparation through the enteral route. Switching to parenteral administration will not only produce systemic effects, that is, the side effects of treating alopecia, but also cause serious complications, because the recovery process of human hair follicles needs to last for a long time Time (up to 2 years, sometimes 3 years for visible results, depending on the area of ​​hair loss and the duration of the hair follicle recovery process)

Images